Chawanun Charnsil1. 1. Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50000, Thailand. charnsil.research@yahoo.com
Abstract
OBJECTIVE: This study aims to examine the efficacy of atomoxetine in treating symptoms of attention deficit hyperactivity disorder (ADHD) in children with severe autistic disorder. METHOD: Children with severe autistic disorder who had symptoms of ADHD were given atomoxetine for 10 weeks. The efficacy of atomoxetine was evaluated by using the Aberrant Behavior Checklist (ABC) to rate ADHD symptoms at baseline, week 6, and week 10. The Clinical Global Impression-Improvement (CGI-I) scale was used as secondary outcome to assess the overall improvement of the children's development at week 10. RESULTS: A total of 12 children participated in this study. Although CGI-I scores showed improvement at week 10, the ABC hyperactivity subscale did not show a significant improvement of the ADHD symptoms at baseline (M = 33.89) compared to those at week 10 (M = 31.78, p = .62). CONCLUSION: Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.
OBJECTIVE: This study aims to examine the efficacy of atomoxetine in treating symptoms of attention deficit hyperactivity disorder (ADHD) in children with severe autistic disorder. METHOD:Children with severe autistic disorder who had symptoms of ADHD were given atomoxetine for 10 weeks. The efficacy of atomoxetine was evaluated by using the Aberrant Behavior Checklist (ABC) to rate ADHD symptoms at baseline, week 6, and week 10. The Clinical Global Impression-Improvement (CGI-I) scale was used as secondary outcome to assess the overall improvement of the children's development at week 10. RESULTS: A total of 12 children participated in this study. Although CGI-I scores showed improvement at week 10, the ABC hyperactivity subscale did not show a significant improvement of the ADHD symptoms at baseline (M = 33.89) compared to those at week 10 (M = 31.78, p = .62). CONCLUSION:Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.
Authors: Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill Journal: CNS Drugs Date: 2015-02 Impact factor: 5.749
Authors: Michael G Aman; Tristram Smith; L Eugene Arnold; Patricia Corbett-Dick; Rameshwari Tumuluru; Jill A Hollway; Susan L Hyman; Marissa Mendoza-Burcham; Xueliang Pan; Daniel W Mruzek; Luc Lecavalier; Lynne Levato; Laura B Silverman; Benjamin Handen Journal: Res Dev Disabil Date: 2014-04-16
Authors: David B Clemow; Chris Bushe; Michele Mancini; Michael H Ossipov; Himanshu Upadhyaya Journal: Neuropsychiatr Dis Treat Date: 2017-02-03 Impact factor: 2.570